Delirium

The grounding supports toxic and metabolic conditions as causes, as well as structural brain lesions. It also links delirium to systemic inflammation in sepsis and to COVID-19-related critical illness, where multiple contributing factors are described. These include direct CNS invasion, inflammatory mediator induction, organ failure, sedative strategies, prolonged mechanical ventilation, immobilization, and environmental factors.

The literature grounding points to neuroinflammation as a central mechanism, including systemic inflammation with microglial activation in the brain. In sepsis-related and post-sepsis states, proposed mechanisms include blood-brain barrier disruption, hypothalamic-pituitary-adrenal axis overactivation, oxidative stress, neurotransmitter dysfunction, programmed cell death, and impaired neuroplasticity. COVID-19-related delirium is also framed as involving CNS inflammatory mediators and possible direct CNS involvement.

Critical illness and sepsis are supported risk contexts for delirium. In COVID-19, accelerated risk is associated with direct CNS invasion, CNS inflammatory mediators, other organ failure, sedative strategies, prolonged mechanical ventilation, immobilization, and adverse environmental factors. The grounding does not support additional general risk factors beyond these settings.

The supplied grounding supports delirium management at the level of diagnosis and supportive ICU-oriented care, but it does not provide a unified treatment standard. The COVID-19 review emphasizes delirium monitoring with a valid tool and management in the context of critical illness. No specific drug class or definitive standard pharmacologic regimen is supported by the grounding.